Which means we get to go (10:39) to the FDA and basically spitball, what does that next study look like? What does that Phase 3 or Phase 4 study going to be? And what can we do from a label perspective? So we are very excited, obviously, to get to that meeting with the FDA later this month (10:52) and have additional guidance from that regulatory group.” We do have Breakthrough Status on this particular drug, which means we get to have multiple FDA meetings. (10:27) “We do have an FDA meeting coming up at the end of this month. (9:42) “And we are in the process of doing an HEOR study right now where we’ll be able to publish and show that de facto.” coli cell line to manufacture this particular product.” It is a protein, so it does require an E. We will be allocating some of our resources directly to manufacturing of this program both potentially for a phase 3 and for preparing for commercialization. And that money was given to us because they decided they were going (5:40) to take a position in the company because of this specific issue. (5:27) “you guys may have seen recently, as of this morning, we raised $12 million that came specifically in the preferred stock offering, from Michael Dell’s fund, MSD Capital. “Potentially an IND sometime next year.” (00:29) (in reference to Alkaline Phosphatase) Rodman & Renshaw Investor Conference, September 12, 2017: Jeffrey Riley